Civil War of the Immune System: Detective Notes on "Failing to Tell Friend from Foe"

The early-morning rheumatology and immunology clinic is never quiet. A 23-year-old female student walks in with a butterfly rash across her face, saying she has been getting short of breath climbing stairs and her fingers are too stiff each morning to turn on the tap. In the next room, a 65-year-old man was woken at midnight by pain in his big toe, now red and swollen like an overripe cherry; he has no idea that the nightcap of sorghum liquor and the diuretic he swallowed after dinner have just conspired to ignite the powder keg in his joint space tonight. A referral letter elsewhere reads: "Woman in her seventies, new-onset temporal headache, jaw pain that stops her chewing halfway through, ESR spiking to 95 — please manage urgently."

These people appear to have nothing in common. Yet the entire discipline of rheumatology and immunology hides inside one shared axis: each of their immune systems, in its own way, has mistaken itself for the enemy. In some, antibodies attack the wrong target; in others, crystals are treated as invaders; in others, neutrophils gnaw holes through the vessel wall; in others, it is simply the central nervous system turning the volume of pain up too high. The exam questions are hard precisely because they never hand you a diagnosis outright — only clues: an antibody, the shape of a crystal, an MRI of the sacroiliac joint, the white cell count of a tube of joint fluid. Your task is to follow the mechanism and trace each thread back to its source.

This issue starts from the detective notes of autoantibodies, walks through the central fog of "pain without inflammation," then turns into the joint space to watch needle-shaped urate crystals quarrel with rhomboid pyrophosphate crystals, climbs the spine all the way to the taxonomy of vessel caliber, and finally settles into the dialogue between synovium and wear-and-tear in rheumatoid arthritis (RA) and osteoarthritis (OA). By the end of each section you will find every exam point strung along the same causal chain.

1. Detective Notes on Autoantibodies: Behind Every Antibody Is a "Self" Under Attack

At first glance, the rheumatology and immunology exam questions look like rote pairing — "see antibody X, think disease Y." But the real skill is not memorizing a table; it is asking each antibody "what is it attacking?" Once you understand that anti-dsDNA attacks double-stranded DNA inside the nucleus, and therefore deposits with immune complexes into the glomerulus to trigger lupus nephritis, and therefore tracks disease activity; that anti-histone arises because a drug has remodeled the antigenicity of histones, so stopping the drug resolves it; that anti-centromere attacks the chromosomal centromere and favors the group of patients whose skin sclerosis stays confined to the fingers — these "pairings" grow on their own the moment you understand them, with no need to memorize. The table below is a quick-reference summary to skim once you have finished the whole section.

Autoantibody	The "self" under attack	Points to
anti-dsDNA	Nuclear double-stranded DNA; deposits into the glomerulus	Systemic lupus erythematosus (SLE) (highly specific; tracks lupus nephritis / disease activity)
anti-Smith (anti-Sm)	Small nuclear ribonucleoproteins of the spliceosome	SLE (highest specificity, low sensitivity, does not track activity)
anti-histone	Histones with drug-remodeled antigenicity	Drug-induced lupus (DIL)
anti-U1RNP (high titer)	U1 small nuclear ribonucleoprotein	Mixed connective tissue disease (MCTD)
anti-centromere	Chromosomal centromere	Limited systemic sclerosis (limited SSc) / CREST
anti-Scl-70 (topo I)	DNA topoisomerase I	Diffuse systemic sclerosis (diffuse SSc), high risk of pulmonary fibrosis
anti-RNA pol III	RNA polymerase III	diffuse SSc, renal crisis, associated with malignancy
anti-SSA(Ro) / anti-SSB(La)	Ro/La ribonucleoproteins	Sjögren's syndrome; anti-Ro crosses the placenta and causes fetal congenital heart block
anti-Jo-1	Histidyl-tRNA synthetase	Polymyositis/dermatomyositis; antisynthetase syndrome (myositis + interstitial lung disease (ILD) + mechanic's hands + Raynaud phenomenon)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The Diagnostic Logic of SLE: ANA Is the Ticket, Not the Answer

🔬 Mechanism, unpacked

The causal chain of SLE unfolds in five steps: genetic susceptibility (HLA-DR2/DR3) → failure of self-tolerance → T-cell/B-cell dysregulation plus impaired clearance of apoptotic cells → antibodies form against nuclear proteins and chromatin (ANA, anti-dsDNA, anti-Sm) → immune complexes deposit into the glomerulus, skin, serosa, and CNS, causing multisystem damage. Clinically this lays out a three-stage read: first screen with the sensitive ANA (>95% sensitive; a negative result nearly excludes SLE), then confirm with the specific anti-dsDNA and anti-Sm (Sm is the most specific but low-sensitivity; dsDNA also tracks activity and nephritis), and finally check for falling complement C3/C4 — this signals that immune complexes are consuming complement, hard evidence of active disease. The 2019 EULAR/ACR criteria fix this chain into a rule: ANA ≥ 1:80 is the entry criterion, and then weighted scoring across 7 clinical domains and 3 immunologic domains applies — a total score ≥ 10 with at least 1 clinical criterion classifies the patient as SLE.

The classic exam signature: a young woman, malar butterfly rash, photosensitivity, polyarticular small-joint pain, elevated anti-dsDNA, falling C3/C4. Hidden here is a detail that is easy to get wrong — CRP is often not elevated during active SLE; a markedly elevated CRP should instead raise suspicion of concurrent infection or serositis, since judging activity by CRP alone will lead you astray.

The cornerstone of treatment must be memorized cold: hydroxychloroquine (HCQ) is the long-term background therapy for every SLE patient — it lowers relapse, reduces organ damage, and improves survival. It is not a "symptom-relief drug" but the backbone that changes the disease course. Long-term, high-dose use can cause retinopathy, so periodic fundoscopic/retinal examination is mandatory alongside it. Acute flares are controlled with corticosteroids; for severe organ involvement such as proliferative lupus nephritis or CNS disease, induction uses cyclophosphamide or mycophenolate mofetil (MMF).

Drug-Induced Lupus: The Pseudo-SLE That Resolves When You Stop the Drug

The differentiating table against primary SLE is easy to memorize once you follow the mechanism:

Feature	Drug-induced lupus (DIL)	Primary SLE
anti-histone	(+) (>95%)	may be (+), not invariable
anti-dsDNA / anti-Sm	usually (−)	often (+)
Complement C3/C4	normal	↓ during activity
Nephritis / CNS involvement	rare	common
Sex distribution	less pronounced	female >> male
Management	stopping the drug usually resolves it	long-term immunotherapy

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The iron rule of DIL: step one is always "stop the drug." Treating it like primary SLE with long-term immunosuppression is therapeutic violence.

Antibody Triage of Connective Tissue Disease: MCTD, CREST, and Diffuse Sclerosis

What the antibody attacks determines what the disease looks like. MCTD is the "nothing-quite-fits" overlap of SLE, SSc, and myositis; Raynaud phenomenon and puffy hands are its signature, and one iron rule governs serologic diagnosis: a high titer of anti-U1RNP is required. Systemic sclerosis splits into two paths by centromere versus topoisomerase antibodies: anti-centromere tracks limited SSc / CREST, in which sclerosis stays confined to the fingers and face — remember the symptoms by the five letters: Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia; anti-Scl-70 (topoisomerase I) tracks diffuse SSc, with widespread skin sclerosis plus pulmonary fibrosis; anti-RNA pol III likewise maps to diffuse disease, but should raise alertness for renal crisis and an association with malignancy.

Sjögren's syndrome attacks the exocrine glands, hence the dry eyes and dry mouth; its antibodies are anti-Ro(SSA) / anti-La(SSB), and a positive rheumatoid factor (RF) is also common. Because the Ro antibody is small enough to cross the placenta, it may leave the mother with nothing worse than dryness while causing the fetus congenital heart block — a detail the exam loves to bury. Clinically, remember one point that is easy to get wrong: Sjögren's extraglandular manifestations such as vasculitis and interstitial nephritis require corticosteroids plus immunosuppressants, not simply artificial tears. The anti-Jo-1 antibody behind polymyositis/dermatomyositis signals antisynthetase syndrome: myositis, interstitial lung disease, mechanic's hands, arthritis, and Raynaud phenomenon arriving together as a set.

Rheumatic Fever: Molecular Mimicry Sends Antibodies After the Wrong Valve

The exam loves asking "is the mechanism immune complex deposition or molecular mimicry?" — remember that rheumatic fever is molecular mimicry; immune complex deposition belongs to other stories (such as IgA vasculitis, cryoglobulinemia, or lupus nephritis).

A Side Note: Two "Immune Exceptions" That Keep Sneaking In

Leukocyte adhesion deficiency (LAD) is an integrin (CD18) defect: neutrophils lose the ability to adhere to the vessel wall and extravasate. Once this mechanism clicks, the counterintuitive exam point makes sense: the circulating neutrophil count is actually elevated (because the cells are stuck inside the vessel with nowhere to go), wounds fail to form pus, and the umbilical cord separates late. Sex distribution also has two famous exceptions: most autoimmune diseases favor women over men (SLE, Sjögren's, Hashimoto's), but type 1 diabetes mellitus (T1DM) affects men and women at similar rates, and ankylosing spondylitis (AS) is more common in men than women — these two are frequently tested reversal traps.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・抗體的偵探筆記Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

The civil war of the immune system is hard to read because the enemy is the self. A twenty-four-year-old female student comes in with a butterfly rash and joint pain; the resident checks an antinuclear antibody, finds it positive, and relaxes, ready to write the diagnosis — but the attending shakes his head and says that is only the ticket, not admission yet. The whole set of rheumatology and immunology antibodies looks like rote pairing, but every antibody has something real that it is attacking, and once you understand that target, the pairing forms in your mind on its own, with no need to force-memorize it. The double-stranded DNA antibody deposits with immune complexes into the glomerulus, so in lupus it rises and falls together with disease activity and nephritis; the Smith antibody attacks the small nuclear ribonucleoproteins inside the spliceosome — highest specificity, unfortunately low sensitivity, but once positive it is almost a signature of lupus; the histone antibody arises because certain drugs remodel the antigenicity of histones, and the immune system treats those remodeled histones as strangers, so stopping the drug resolves it.

The antinuclear antibody is only the ticket, not the answer — specific antibodies plus falling complement are the real hard evidence that lupus is active.

The mechanism of lupus can be broken into five steps: genetic susceptibility comes first, then failure of self-tolerance, then T-cell and B-cell dysregulation combined with poor clearance of apoptotic cells, which leads to a set of antibodies against nuclear proteins and chromatin, and finally immune complexes deposit into the glomerulus, skin, serosa, and CNS, causing multisystem damage. The diagnostic logic is therefore likewise three-staged: first screen with the sensitive antinuclear antibody, whose sensitivity exceeds ninety-five percent so that almost every lupus patient is positive — its value lies in a negative result excluding the diagnosis, but its specificity is low, since healthy people and other autoimmune diseases can also be positive, which is why treating it as the answer leads you astray. The next step adds double-stranded DNA and Smith antibodies; the 2019 joint European-American criteria fixed this chain into a rule, with the entry criterion being an antinuclear antibody of 1:80 or higher, followed by weighted scoring across seven clinical domains and three immunologic domains, and only a total score of ten or more with at least one clinical criterion classifies the patient as lupus. Complement is consumed and falls during active disease as immune complexes use it up, which is why it serves as a marker of activity; but C-reactive protein is often not elevated in uncomplicated lupus, so if it rises markedly, one should first suspect concurrent infection or serositis rather than assume the disease itself has worsened. The cornerstone of treatment is the quinine-class drug hydroxychloroquine, which is not a symptom-relief agent but the backbone that changes the disease course — it lowers relapse, reduces organ damage, and improves survival, though long-term high-dose use causes retinopathy, so periodic fundoscopy is required; acute flares are controlled with corticosteroids, and for severe organ involvement such as proliferative lupus nephritis or CNS disease, induction requires cyclophosphamide or mycophenolate mofetil.

The antinuclear antibody is only the ticket, not the answer — specific antibodies plus falling complement are the real hard evidence that lupus is active.

Drug-induced lupus is a clean branch off this main line. The usual culprit drugs form a mnemonic called HIP — hydralazine, isoniazid, procainamide — plus minocycline, anti-TNF agents, quinidine, and others. The mechanism is that in people with a slow-acetylator phenotype, these drugs remodel the antigenicity of histones, and the immune system treats these remodeled histones as foreign, producing anti-histone antibodies; but this reaction stays shallow and never reaches the double-stranded DNA and Smith layer, and complement is not consumed, so the kidneys and central nervous system are left alone. The differentiating table makes sense once you follow the mechanism: drug-induced disease shows a positive histone antibody while double-stranded DNA and Smith are negative, complement is normal, and the sex difference is not pronounced. The iron rule of management is to stop the drug — treating it like primary lupus with long-term immunosuppression is therapeutic violence; at most, severe symptoms are carried through with a short course of anti-inflammatories or low-dose steroids. Each connective tissue disease is triaged by a different antibody, because what the antibody attacks determines what the disease looks like. Mixed connective tissue disease is the nothing-quite-fits overlap of lupus, sclerosis, and myositis, with Raynaud phenomenon and puffy hands as its signature, and the hard evidence is a high titer of the U1 ribonucleoprotein antibody. Systemic sclerosis splits into two paths by centromere and topoisomerase antibodies: the centromere antibody tracks limited sclerosis, namely CREST, where sclerosis stays confined to the fingers and face, with the five-piece set being calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; the topoisomerase type I antibody tracks diffuse disease, with widespread skin sclerosis plus pulmonary fibrosis; the RNA polymerase type III antibody likewise maps to diffuse disease, but should raise alertness for renal crisis and malignancy. Sjögren's syndrome attacks the exocrine glands, hence the dry eyes and dry mouth, with Ro and La as its antibodies; the Ro antibody is small enough to cross the placenta, so the mother may have nothing worse than dryness while the fetus can develop congenital heart block because its conduction system is struck — a detail the exam loves to bury; Sjögren's extraglandular manifestations, such as vasculitis and interstitial nephritis, require corticosteroids plus immunosuppression, not simply artificial tears. Behind the Jo-1 antibody of polymyositis and dermatomyositis lies antisynthetase syndrome, in which myositis, interstitial lung disease, mechanic's hands, arthritis, and Raynaud phenomenon all arrive together as a set.

The antinuclear antibody is only the ticket, not the answer — specific antibodies plus falling complement are the real hard evidence that lupus is active.

Rheumatic fever is another story of the self mistaken for the enemy, and its five-step causal chain unfolds like this: after group A β-hemolytic streptococcal pharyngitis, the bacterium's M protein happens to resemble antigens in human myocardium, valves, and joint synovium; the antibodies the immune system manufactures engage in molecular mimicry, and while attacking the bacteria they also strike the body's own valves — a textbook case of type II hypersensitivity. It therefore strikes two to four weeks after the pharyngitis, because time is needed to manufacture the antibodies. The Jones major criteria include carditis, migratory polyarthritis, Sydenham chorea, erythema marginatum, and subcutaneous nodules, and the most classic long-term sequela is mitral stenosis. The exam loves asking whether the mechanism is molecular mimicry or immune complex deposition — remember that rheumatic fever is molecular mimicry, while immune complex deposition belongs to the stories of IgA vasculitis, cryoglobulinemia, and lupus nephritis. Finally, two immune exceptions that keep sneaking in deserve special emphasis: leukocyte adhesion deficiency is an integrin defect in which neutrophils lose the ability to adhere to the vessel wall and extravasate, so the circulating neutrophil count actually rises, wounds fail to form pus, and the umbilical cord separates late; most autoimmune diseases favor women over men, but type 1 diabetes affects men and women similarly and ankylosing spondylitis is more common in men than women — these two are frequently tested reversal traps. Hold onto the core question of what the antibody is attacking throughout this chapter, and the pairings will grow on their own once you understand it.

2. Pain Without Inflammation: The Central Fog of Fibromyalgia

The group most often misunderstood in rheumatology and immunology is patients with fibromyalgia. The exam's core question is always the same sentence: this is a disease in which the central nervous system amplifies the pain signal, not a disease in which tissue is inflamed. Once you accept this axis, every seemingly contradictory clue becomes self-evident.

The Knife That Cuts It Away from Inflammatory Rheumatic Disease Is Called "Markers"

🔬 Mechanism, unpacked

The causal chain of fibromyalgia breaks into five steps: genetic susceptibility plus a stress trigger → failure of descending inhibitory pathways (insufficient serotonin- and norepinephrine-mediated inhibition) → hyperexcitability of dorsal horn neurons with elevated substance P → central sensitization and a lowered pain threshold → widespread body-wide pain plus fatigue, unrefreshing sleep, and cognitive impairment. This chain therefore runs through "abnormal signal processing," not "tissue destruction" — the joints are not being gnawed, the muscles are not under attack, so blood work naturally shows no evidence of inflammation whatsoever: CRP/ESR normal, autoantibodies negative, imaging shows no destruction. In other words, the pain in this disease is real, but the inflammation is not.

Once this axis is established, the differentiating table is just the same sentence written a different way:

Disease	CRP / ESR	Autoantibodies	Imaging / objective findings	Key features
Fibromyalgia	Normal	Negative	No destruction	Widespread pain, fatigue, poor sleep — all tests normal
Rheumatoid arthritis (RA)	Elevated	RF, anti-CCP(+)	Erosions in symmetric small joints	Morning stiffness >1 hour
Systemic lupus erythematosus (SLE)	ESR↑ (CRP often not elevated), complement↓	ANA, anti-dsDNA(+)	—	Butterfly rash, multisystem involvement
Ankylosing spondylitis (AS)	Elevated	HLA-B27(+)	Sacroiliitis, bamboo spine	Inflammatory low back pain, nocturnal pain
Polymyalgia rheumatica (PMR)	Markedly elevated (ESR often >50)	—	—	Age >50, shoulder/hip girdle pain, dramatic response to low-dose steroids

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

When the question gives you "whole-body aching + normal CRP/ESR + negative antibodies + normal imaging" — the answer is fibromyalgia; the moment an inflammatory marker rises, think toward a genuine inflammatory rheumatic disease instead.

Diagnosis Is a Scale-Based Clinical Judgment — Not Blood Work, Not Imaging

Fibromyalgia is a clinical diagnosis, resting on two scales from the 2010/2016 American College of Rheumatology (ACR) criteria: the Widespread Pain Index (WPI), which scores the number of painful sites over the past week, and the Symptom Severity Scale (SSS), which scores fatigue, unrefreshing sleep, cognitive symptoms, and the severity of somatic symptoms, plus a symptom duration of ≥ 3 months with other explanatory diseases excluded. One important conceptual update: the old "18 tender points" has been replaced by the questionnaire-based scales and is no longer a rigid threshold; the 2016 version further requires that the pain be widely distributed, to avoid misclassifying localized pain as fibromyalgia.

The role each test plays in this disease must be sorted into "ruling out" versus "confirming":

Test	Role in fibromyalgia	Why it is not a confirmatory tool
CRP / ESR	Rules out inflammatory disease	Normal in fibromyalgia itself; cannot "detect" it
RF / anti-CCP	Screens for RA	Used for RA, not for diagnosing fibromyalgia
Cervical / lumbar MRI	Rules out nerve root compression, myelopathy	A normal image cannot confirm the diagnosis
TSH	Rules out hypothyroidism (which also causes fatigue and aching)	Used for differentiation
Hormone panels	Unrelated to the diagnosis of fibromyalgia	Not a diagnostic tool

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Treatment Also Follows the Mechanism: Because There Is No Inflammation, NSAIDs and Steroids Are Essentially Useless

Because the core problem is central sensitization rather than inflammation, treatment naturally centers on non-pharmacologic therapy — exercise and patient education — as first line; the drugs chosen are those that modulate central pain processing — antidepressants (duloxetine, amitriptyline) and anticonvulsants (pregabalin, gabapentin). Conversely, NSAIDs and steroids are essentially useless, because they act on "inflammation," and the lesion here is never inflammation to begin with. This is a frequently tested reversal trap: the question describes fibromyalgia, and the options offer NSAIDs and low-dose steroids — that is the wrong direction.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・會痛，但不發炎Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

A forty-two-year-old woman has had whole-body aching for more than six months, wakes up groggy no matter how much she sleeps, cannot concentrate, and tosses and turns at night; she has been to three hospitals where blood work, imaging, and antibodies all came back normal, the first two doctors suspected she was faking it, and the third gave her sleeping pills, resolving nothing. The group most often misunderstood in rheumatology and immunology is patients with fibromyalgia, and the exam's core question is always the same sentence: this is a disease in which the central nervous system amplifies the pain signal, not a disease in which tissue is inflamed. Once this axis is accepted, every seemingly contradictory clue becomes self-evident.

This is a disease of the central nervous system turning up the volume on pain, not a disease of inflamed tissue — so every marker stays normal while the pain is still real.

The five-step mechanism chain runs as follows: genetic susceptibility and a stress trigger come first, then insufficient serotonin- and norepinephrine-mediated inhibition along the descending inhibitory pathways, which leads to hyperexcitable dorsal horn neurons and elevated substance P, producing central sensitization and a lowered pain threshold, and finally presenting as widespread body-wide pain plus fatigue, poor sleep, and cognitive impairment. This path is therefore one of abnormal signal processing rather than tissue destruction. The joints are not being gnawed and the muscles are not under attack, so blood work naturally shows no evidence of inflammation whatsoever — C-reactive protein and ESR are normal, autoantibodies are negative, imaging shows no destruction; the pain in this disease is real, but the inflammation is not. Once this axis is established, the differentiating table is just the same sentence written a different way: when the question gives whole-body aching plus every marker normal plus negative antibodies plus normal imaging, the answer is fibromyalgia; the moment an inflammatory marker rises, think toward a genuine inflammatory rheumatic disease instead, since rheumatoid arthritis, lupus, ankylosing spondylitis, and polymyalgia rheumatica each have their own pattern of elevation and corresponding antibody or gene. Polymyalgia rheumatica deserves special note: age over fifty, shoulder-and-hip-girdle pain, ESR often spiking above fifty, and a dramatic response to low-dose steroids — a completely different scent from fibromyalgia's normal markers.

This is a disease of the central nervous system turning up the volume on pain, not a disease of inflamed tissue — so every marker stays normal while the pain is still real.

Diagnosis is a scale-based clinical judgment, resting on neither blood work nor imaging. The 2010 and 2016 American College of Rheumatology criteria rely on two scales: the Widespread Pain Index scores the number of painful sites over the past week, and the Symptom Severity Scale scores fatigue, unrefreshing sleep, cognitive symptoms, and the severity of somatic symptoms, plus a symptom duration of at least three months with other explanatory diseases excluded. One conceptual update worth remembering: the old eighteen tender points have been replaced by the questionnaire-based scales and are no longer a rigid threshold; the 2016 version further requires that the pain be widely distributed, to avoid misclassifying localized pain as fibromyalgia. Every test in this disease plays only the role of ruling out something else, never of confirming it: C-reactive protein and ESR rule out inflammatory disease, rheumatoid factor and anti-cyclic citrullinated peptide antibody screen for rheumatoid arthritis, cervical and lumbar MRI rule out nerve root compression and myelopathy, thyroid-stimulating hormone rules out hypothyroidism, and hormone panels are unrelated to the diagnosis. In other words, fibromyalgia has no positive confirmatory test — every blood draw and image exists to rule out something else, not to detect it, and treating rheumatoid factor as the gold standard for fibromyalgia is using a screening tool in the wrong place.

This is a disease of the central nervous system turning up the volume on pain, not a disease of inflamed tissue — so every marker stays normal while the pain is still real.

Treatment also follows the mechanism. Because the core problem is central sensitization rather than inflammation, the main approach is non-pharmacologic therapy — exercise and patient education — as first line; the drugs chosen modulate central pain processing: the antidepressants duloxetine and amitriptyline, the anticonvulsants pregabalin and gabapentin — what they share is that they directly modulate the central pain-processing circuit rather than suppressing inflammation; conversely, anti-inflammatory analgesics and steroids are essentially useless, because they act on inflammation and the lesion here is never inflammation to begin with. This is a frequently tested reversal trap: the question describes fibromyalgia, and the options offer anti-inflammatory analgesics and low-dose steroids — that is the wrong direction. Strung together, this whole chapter is really just different faces of the same principle: an amplified signal is not the same as damaged tissue, so normal inflammatory markers are no contradiction, negative antibodies are no contradiction, and unremarkable imaging is no contradiction; diagnosis rests on scales, treatment targets the center — once this causal chain clicks, seeing whole-body aching plus normal markers tells you at once which direction to head.

3. Two Crystal Wars Inside the Joint Space: Gout and Pseudogout

Shape and Color Under Polarized Light

Aspirating joint fluid for polarized-light microscopy is the gold standard for diagnosing both: seeing crystals engulfed by white cells confirms the diagnosis, whereas relying on serum uric acid or X-ray alone leads you astray.

🔬 Mechanism, unpacked

The causal chain of gout unfolds in five steps: hyperuricemia (usually the under-excretion type) → monosodium urate (MSU) crystals precipitate in the joint space → the crystals are engulfed by macrophages, activating the NLRP3 inflammasome → IL-1β is released → massive neutrophil infiltration produces redness, swelling, heat, and pain. Pseudogout (CPPD, calcium pyrophosphate deposition) differs in that the crystal precipitating out is calcium pyrophosphate (CPPD crystal), but downstream it runs through the same NLRP3 pathway, so colchicine and IL-1 inhibitors are effective for both. Under polarized light the two crystals differ in shape and the direction of their birefringence: gout crystals are needle-shaped with strong negative birefringence — when the crystal's long axis lies parallel to the slow axis of the red compensator it appears yellow, and blue when perpendicular; CPPD crystals are rhomboid with weak positive birefringence — blue when parallel, yellow when perpendicular, exactly the reverse. Remember the mnemonic "Negative = Gout," and the question will never trip you up.

Feature	Gout	Pseudogout (CPPD)
Crystal composition	MSU (monosodium urate)	CPPD (calcium pyrophosphate)
Shape	Needle-shaped	Rhomboid
Birefringence	Strongly negative	Weakly positive
Color (parallel to slow axis)	Yellow (blue if perpendicular)	Blue (yellow if perpendicular)
Favored joint	First metatarsophalangeal joint (podagra, the big toe)	Knee, wrist
X-ray clue	Chronic disease shows bone erosion (punched-out lesion)	Chondrocalcinosis

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

"Needle, negative, yellow, big toe" is gout; "rhomboid, positive, blue, knee" is pseudogout. Memorize these two four-word tags cold, and the polarized-light question becomes a coin flip you can't lose.

Leave Uric Acid Alone During an Acute Flare: Timing Logic Is the Heart of the Question

🔬 Mechanism, unpacked

Why can't you start a urate-lowering drug during an acute flare? Because the essence of acute inflammation is a fire lit by crystals being engulfed by white cells inside the joint space, detonating IL-1β — if you give allopurinol or febuxostat at this point and crash the serum uric acid, it will destabilize and dissolve the urate crystals already deposited in tissue, which paradoxically triggers or worsens the flare. Whether uric acid rises or falls, any sharp swing in either direction lights the fire. The timing is therefore an iron rule: during the acute phase, only put out the fire — leave uric acid alone; only 2–4 weeks after remission do you begin lowering it. A patient already on a urate-lowering drug who has an acute flare should not stop the drug, because stopping likewise causes a swing in uric acid.

Acute flare → anti-inflammatory analgesia (put out the fire): NSAID / colchicine / corticosteroid

do not start allopurinol / febuxostat

2-4 weeks after remission → only then begin urate-lowering therapy

(co-prescribe colchicine at initiation to prevent flare)

Two counterintuitive but frequently tested points remain: first, serum uric acid can fall within the normal range during an acute flare — because uric acid excretion increases during inflammation, and the crystals were already deposited in the joint long before, so a normal serum uric acid cannot exclude gout; the diagnosis still rests on joint-fluid crystals. Second, asymptomatic hyperuricemia is, as a rule, not routinely treated with urate-lowering therapy — if it is only elevated with no flare and no stones, there is no need to start medication right away.

🦦

PipThis patient has severe big-toe pain and a serum uric acid of 9.5 — I'll start allopurinol right away to bring the uric acid down! And since he's on a thiazide, I'll add an aspirin for pain relief too!

🐻‍❄️

BarnabyBoth moves are landmines. Starting a urate-lowering drug during the acute phase triggers or worsens the flare — a rapid drop in uric acid destabilizes the crystals already in tissue; during the acute phase you need NSAIDs, colchicine, or corticosteroids to put out the fire, and urate-lowering therapy waits until two to four weeks after remission. Low-dose aspirin also inhibits uric acid excretion and raises uric acid, making it the same gasoline-on-the-fire combination as the thiazide. Remember: acute phase = fire only, leave uric acid alone; a normal uric acid still cannot exclude gout.

Drugs and Genes: Thiazide, Aspirin, HLA-B*58:01

Common drugs that affect uric acid are a major source of exam questions, and the mechanism always comes down to "excretion":

Drug	Effect on uric acid	Mechanism
Thiazide / loop diuretics	Raises (triggers gout)	Reduces uric acid excretion
Low-dose aspirin	Raises (inhibits excretion)	Low doses inhibit uric acid excretion; only high doses promote it
Losartan	Mildly lowers	Also promotes uric acid excretion (an option for hypertension with comorbid gout)
cyclosporine, pyrazinamide, ethambutol	Raises	Inhibits excretion

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The last piece of the puzzle is pharmacogenomics: allopurinol can trigger severe cutaneous adverse reactions — SJS/TEN, DRESS — and the risk rises sharply in patients positive for HLA-B*58:01; the carrier rate is high in the Han Chinese (Taiwanese) population, so screen for HLA-B*58:01 before starting the drug, and switch to another agent if positive (febuxostat still warrants caution). A paired mnemonic: allopurinol → B*58:01; carbamazepine → B*15:02 — both lead to SJS/TEN.

⭐ Board-exam essentials

Gout and Pseudogout

Gold-standard diagnosis = polarized-light microscopy of joint fluid for crystals (not X-ray or serum uric acid).
Gout = needle, negative, yellow, big toe; CPPD = rhomboid, positive, blue, knee; CPPD's X-ray sign is chondrocalcinosis.
Shared downstream pathway = NLRP3 inflammasome → IL-1β, so colchicine / IL-1 inhibitors work for both.
Serum uric acid can be normal during an acute flare — it cannot be used to exclude the diagnosis; asymptomatic hyperuricemia is not routinely treated.
During the acute phase, only put out the fire (NSAID / colchicine / corticosteroid) — do not start allopurinol / febuxostat (current ACR 2020 conditionally allows starting during a flare under anti-inflammatory cover); patients already taking one should not stop it.
Thiazides and low-dose aspirin raise uric acid (inappropriate choices in gout); losartan lowers it slightly.
allopurinol → HLA-B*58:01 → SJS/TEN (screen before use in the Han Chinese population); compare carbamazepine → B*15:02.
Traps: starting allopurinol during the acute phase; using aspirin for pain relief; excluding gout because uric acid is normal; forgetting HLA-B*58:01 screening.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・結晶在關節腔裡的兩場戰爭Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

The old man woken at midnight by pain is sixty-seven, never misses sorghum liquor and organ meats at a meal, and recently started a diuretic for hypertension; at four this morning the big toe on his left foot is red, swollen, and shiny, screaming at the lightest touch. Next door, the grandmother's knee suddenly swelled up, with a thin white line of cartilage calcification on X-ray. Two joints that are both acutely red, swollen, hot, and painful — one crystal a needle, the other a rhombus — and the moment the aspirated joint fluid is viewed under polarized light, the two stories fork apart. The gold standard for diagnosis is polarized-light microscopy of joint fluid showing crystals engulfed by white cells; relying on serum uric acid or X-ray alone leads you astray.

During an acute flare, only put out the fire and leave uric acid alone — because a sharp swing in either direction will light it.

The mechanism of gout can be broken into five steps: hyperuricemia, usually the under-excretion type, comes first; monosodium urate crystals precipitate in the joint space; the crystals are engulfed by macrophages, activating the NLRP3 inflammasome; IL-1β is released; and finally massive neutrophil infiltration produces redness, swelling, heat, and pain — once this chain clicks, it is clear why colchicine and IL-1 inhibitors can put out the fire. The gout crystal is monosodium urate, needle-shaped, with strong negative birefringence: when the crystal's long axis lies parallel to the slow axis of the red compensator it appears yellow, and blue when perpendicular; the pseudogout crystal is calcium pyrophosphate, rhomboid, with weak positive birefringence — blue when parallel and yellow when perpendicular, exactly the reverse — yet downstream it runs through the same NLRP3 pathway, so colchicine is effective for both in treatment. The favored sites are also cleanly divided: gout favors the big toe, pseudogout favors the knee, and on X-ray pseudogout shows a thin white line of cartilage calcification. Memorize the eight words needle, negative, yellow, big toe against rhomboid, positive, blue, knee, and the polarized-light question becomes a coin flip you can't lose.

During an acute flare, only put out the fire and leave uric acid alone — because a sharp swing in either direction will light it.

Timing logic is the heart of the question. Why can't a urate-lowering drug be started during an acute flare? Because the essence of acute inflammation is a fire lit by crystals being engulfed by white cells inside the joint space and detonating; if you give a xanthine oxidase inhibitor at this point and crash the serum uric acid, it will destabilize and dissolve the urate crystals already deposited in tissue, which paradoxically triggers or worsens the flare — whether uric acid rises or falls, any sharp swing in either direction lights the fire. The iron rule is therefore that the acute phase uses only anti-inflammatory analgesia, colchicine, or corticosteroids to put out the fire, and urate-lowering therapy begins only two to four weeks after remission, with colchicine co-prescribed at the start to prevent recurrence. A patient already on a urate-lowering drug who has an acute flare should not stop it, because stopping likewise causes a swing in uric acid. Two counterintuitive but frequently tested points deserve emphasis: serum uric acid can fall within the normal range during an acute flare, because uric acid excretion increases during inflammation and the crystals were already deposited in the joint, so a normal serum uric acid cannot exclude gout; and asymptomatic hyperuricemia is, as a rule, not routinely treated with urate-lowering therapy — if it is only elevated with no flare and no stones, there is no need to start medication right away. The common drugs that affect uric acid all work through excretion: diuretics reduce excretion and raise uric acid, low-dose aspirin also inhibits excretion and raises it, while losartan also promotes excretion and therefore lowers it slightly, making it a preferred choice for hypertension with comorbid gout.

During an acute flare, only put out the fire and leave uric acid alone — because a sharp swing in either direction will light it.

The last piece of the puzzle is pharmacogenomics: allopurinol can trigger severe cutaneous adverse reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis, and the risk rises sharply in patients positive for HLA-B*58:01; the carrier rate is high in the Han Chinese Taiwanese population, so screening for HLA-B*58:01 before starting the drug is required, with another agent substituted if positive. A paired mnemonic: carbamazepine corresponds to HLA-B*15:02, and both lead to severe skin-necrosis reactions. Hold onto the main line of crystals activating NLRP3 and IL-1β throughout this chapter, together with the iron rule of leaving uric acid alone during the acute phase, and the question becomes a coin flip you can't lose.

4. The Enthesis Family: The Spectrum of Spondyloarthritis Strung Together by HLA-B27

Spondyloarthritis (SpA) is not a single disease but a family that shares a common set of features.

Grasp the family's shared features as a five-piece set: enthesitis (Achilles tendon, plantar fascia pain), axial involvement (sacroiliitis/spondylitis; inflammatory low back pain — worse with rest, better with activity, morning stiffness >30 minutes, pain that wakes the patient at night), HLA-B27 association (familial clustering, RF-negative, hence the name seronegative spondyloarthritis), dactylitis (sausage digit), and extra-articular features (uveitis, psoriasis, inflammatory bowel disease, IBD).

Ankylosing Spondylitis (AS): From MRI Bone Marrow Edema to the Bamboo Spine

AS favors men aged 20–30 (male:female roughly 2–3:1), with an HLA-B27 positivity rate of about 90% — yet only a minority of B27-positive carriers ever develop the disease, so B27 alone cannot make the diagnosis. The clinical reasoning chain runs sacroiliitis → ascending spinal stiffness → ligamentous ossification (syndesmophyte) → the X-ray's "bamboo spine." The physical exam commonly uses the Schober test to assess lumbar forward flexion, along with chest expansion. The most common extra-articular finding is acute anterior uveitis/iritis (25–40%); don't forget aortic regurgitation and upper-lobe pulmonary fibrosis.

Imaging sequence	Features
Earliest (invisible on X-ray)	MRI shows sacroiliac bone marrow edema
Early X-ray	Sacroiliac joints show blurred margins, erosion, pseudo-widening
Late	Sacroiliac joints fuse; spine shows syndesmophytes / bamboo spine

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The modern classification (ASAS) labels patients who already show structural damage on X-ray as radiographic axial SpA (= AS), while those with normal X-rays but sacroiliac inflammation already visible on MRI are non-radiographic axial SpA (nr-axSpA) — the two are simply the early and late ends of the same disease spectrum, which is why MRI can catch early patients before X-ray ever can.

The treatment ladder has two points worth memorizing cold: first line is NSAIDs + exercise/physical therapy — and continuous use suppresses ossification better than as-needed use; only after NSAIDs fail do you switch to a biologic (anti-TNF, or an IL-17 inhibitor such as secukinumab or ixekizumab); by 2026, JAK inhibitors (tofacitinib, upadacitinib) have also been listed as an advanced oral option. Sulfasalazine works only on peripheral joints and is useless for axial disease; conventional DMARDs (methotrexate, sulfasalazine) are useless for axial disease; oral corticosteroids likewise perform poorly for axial AS — completely unlike RA, and a frequently tested reversal trap.

Reactive Arthritis and Other Forms of SpA

The mechanism of reactive arthritis is 1–4 weeks after a distant gastrointestinal or genitourinary infection, triggering sterile arthritis (no organism is found in the joint space) — it is a post-infectious immune reaction, not the infection itself. The classic triad is arthritis + conjunctivitis + urethritis ("can't see, can't pee, can't climb a tree"); remember the triggering organisms: genitourinary Chlamydia trachomatis, enteric Shigella, Salmonella, Yersinia, Campylobacter — Clostridium does not trigger it (the exam key, though rare C. difficile–associated cases have been reported), a high-frequency trap option. Also remember that Chlamydia causes reactive arthritis/conjunctivitis/urethritis, not infective endocarditis — another common decoy.

The HLA associations of the other forms of SpA must be kept straight:

Disease	HLA association	Joint features
Ankylosing spondylitis (AS)	HLA-B27 (~90%)	Predominantly axial, sacroiliac
Psoriatic arthritis	HLA-Cw6 (for psoriasis itself); the arthritic form is also linked to B27	Can involve the DIP joints, sausage digits, "pencil-in-cup" deformity, nail pitting
Reactive arthritis	HLA-B27	Asymmetric large joints of the lower limb
Inflammatory bowel disease (IBD)-associated arthritis	HLA-B27	Peripheral joint activity tracks bowel inflammation activity

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

A paired mnemonic: for psoriasis, look at skin and nails and remember HLA-Cw6; for the spine, look at the sacroiliac joints and remember HLA-B27; rheumatoid arthritis (RA) is the one tested with HLA-DR4.

⭐ Board-exam essentials

Spondyloarthritis (SpA)

Primary lesion = the enthesis; not the synovium (RA), not cartilage (OA).
Mechanistic axis = HLA-B27 + IL-23/IL-17 → enthesitis → reparative ossification.
AS: male > female, age 20–30, HLA-B27 ~90%; inflammatory low back pain = worse with rest, morning stiffness >30 minutes, wakes the patient at night.
Earliest imaging finding = MRI sacroiliac bone marrow edema; late finding = bamboo spine (syndesmophytes).
Treatment: NSAIDs + exercise as first line (used continuously); on failure, anti-TNF / IL-17 inhibitors; on further failure, JAK inhibitors; methotrexate / sulfasalazine are useless for axial disease (sulfasalazine only rescues peripheral joints).
Most common extra-articular finding = acute anterior uveitis.
Reactive arthritis: 1–4 weeks after a GI/genitourinary infection; triad = arthritis + conjunctivitis + urethritis; triggering organisms include Chlamydia / Shigella / Salmonella / Yersinia / Campylobacter — Clostridium does not trigger it.
HLA: psoriasis itself = Cw6; spine = B27; RA = DR4.
Traps: choosing methotrexate or oral steroids first-line for AS; using sulfasalazine to treat axial disease; pairing Chlamydia with infective endocarditis; naming Clostridium as a trigger of reactive arthritis.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・附著點的家族Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

The axis of spondyloarthritis is a story of the immune system attacking the wrong place in a different organ. Its primary lesion sits at the point where tendon and ligament attach to bone, not rheumatoid arthritis's synovium and not degenerative cartilage. The causal chain strings together in five steps: first the susceptible HLA-B27 constitution plus a trigger from gut flora or mechanical stress, then local immune activation at the enthesis, switching on the Th17 axis of IL-23 plus IL-17, producing enthesitis; after the inflammation, the body launches repair, and excessive repair means ossification, so bone spurs and bony bridges eventually grow and cause stiffness. Once this mechanism clicks, the bamboo spine, the enthesis pain, why treatment calls for continuous rather than as-needed anti-inflammatory analgesics, and why IL-17 inhibitors work all make sense. Grasp the family's shared features as a five-piece set: enthesitis at the Achilles tendon and plantar fascia; axial involvement whose inflammatory low back pain is worse with rest, better with activity, with morning stiffness over thirty minutes and pain that wakes the patient at night; an HLA-B27 association with a negative rheumatoid factor; dactylitis presenting as sausage digits; and extra-articular features of uveitis, psoriasis, and inflammatory bowel disease.

The enthesis is the primary lesion, IL-23 plus IL-17 is the spark, and the bamboo spine is the result of repair gone into overdrive.

Ankylosing spondylitis favors men aged twenty to thirty, with a male-to-female ratio of roughly two or three to one; the B27 positivity rate is about ninety percent, but only a minority of carriers ever develop the disease, so B27 alone cannot make the diagnosis. The clinical reasoning is that the sacroiliac joints become inflamed first, followed by ascending spinal stiffness, ligamentous ossification growing bony bridges, and an X-ray that shows a bamboo spine. The imaging sequence is highly instructive: while X-ray still shows nothing, MRI can already reveal sacroiliac bone marrow edema, which is why the modern classification labels patients who already show structural damage on X-ray as radiographic axial disease, and those whose X-ray remains normal but whose MRI already shows inflammation as non-radiographic axial disease — the two are simply the early and late ends of the same disease spectrum, and MRI can catch early patients before X-ray ever can. The most common extra-articular finding is acute anterior uveitis, or iritis; don't forget aortic regurgitation and upper-lobe pulmonary fibrosis. The treatment ladder has two points worth memorizing cold: first line is anti-inflammatory analgesics plus exercise and physical therapy, and continuous use suppresses ossification better than as-needed use; only after failure do you switch to a biologic such as an anti-TNF agent or an IL-17 inhibitor such as secukinumab or ixekizumab, and only after that fails do you move to a JAK inhibitor. Sulfasalazine works only on peripheral joints and is useless for axial disease, conventional disease-modifying antirheumatic drugs are equally powerless against axial disease, and oral corticosteroids likewise perform poorly for axial disease — the complete opposite of rheumatoid arthritis, and a frequently tested reversal trap.

The enthesis is the primary lesion, IL-23 plus IL-17 is the spark, and the bamboo spine is the result of repair gone into overdrive.

Reactive arthritis is another family member likewise linked to B27; its mechanism is sterile arthritis triggered one to four weeks after a distant gastrointestinal or genitourinary infection, with no organism found in the joint space — it is a post-infectious immune reaction, not the infection itself. The classic triad is arthritis plus conjunctivitis plus urethritis; the triggering organisms include Chlamydia for the genitourinary tract and Shigella, Salmonella, Yersinia, and Campylobacter for the gut, with Clostridium not a trigger — a high-frequency trap. Chlamydia causes reactive arthritis rather than infective endocarditis, which is also a common decoy. The other HLA associations must be kept straight: psoriasis itself corresponds to Cw6, the spine corresponds to B27, and rheumatoid arthritis is the one tested with DR4. Psoriatic arthritis can involve the distal interphalangeal joints, sausage digits, a pencil-in-cup deformity, and nail pitting. Inflammatory bowel disease-associated arthritis, meanwhile, has peripheral joint activity that tracks bowel inflammation activity. Hold onto the core idea of the enthesis as the primary lesion throughout this chapter, and everything from the imaging sequence to the choice of biologic follows naturally from it.

The enthesis is the primary lesion, IL-23 plus IL-17 is the spark, and the bamboo spine is the result of repair gone into overdrive.

5. The Taxonomy of Vessel Caliber: From Temporal Headache to ANCA-Positive Small Vessels

Vasculitis is a disease in which the immune system attacks the vessel wall, and the exam's skeleton is simple: first sort by "vessel caliber" into large, medium, and small, then use ANCA subtype to pin down the small-vessel vasculitides.

Building the Skeleton by Caliber

Caliber	Representative diseases	One-line feature
Large vessel	Giant cell arteritis (GCA), Takayasu arteritis	GCA: elderly, temporal artery, vision; Takayasu: young Asian women, pulseless
Medium vessel	Polyarteritis nodosa (PAN), Kawasaki disease	PAN: often associated with HBV, spares the lung, beaded aneurysms; Kawasaki: coronary artery aneurysms in children
Small vessel (ANCA-associated)	GPA, MPA, EGPA	Pulmonary-renal syndrome, ANCA-positive
Small vessel (immune complex)	IgA vasculitis (HSP), cryoglobulinemic vasculitis	HSP in children: palpable purpura + abdominal pain + nephritis; cryoglobulinemic often associated with HCV

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

ANCA-Associated Vasculitis: Mechanism Decides Everything

🔬 Mechanism, unpacked

The causal chain of ANCA-associated vasculitis (AAV) runs in five steps: autoantibodies (ANCA) form against the neutrophil cytoplasmic enzymes PR3 or MPO → infection or environmental stimuli make neutrophils express these antigens on their surface → ANCA binds → neutrophils become hyperactivated, degranulate, and release NETs → the small-vessel endothelium is attacked → necrotizing vasculitis and necrotizing glomerulonephritis result. AAV is therefore an autoimmune disease, a different animal from "autoinflammatory disease (innate immune / inflammasome dysregulation)," the category that includes diseases like familial Mediterranean fever; the exam loves labeling GPA as autoinflammatory as a decoy — remember that AAV is autoimmune and you won't be fooled. Then use "is the antigen PR3 or MPO, is the ANCA c or p" to split the three small-vessel vasculitides apart.

Disease	ANCA subtype	Target	Clinical iron triad
GPA (granulomatosis with polyangiitis, formerly Wegener's)	c-ANCA (highest positivity rate)	PR3	Upper airway (sinuses, saddle nose) + lower airway (pulmonary nodules/cavities) + kidney (necrotizing glomerulonephritis), with granulomas
MPA (microscopic polyangiitis)	p-ANCA	MPO	Pulmonary-renal syndrome but no granulomas, no upper-airway destruction
EGPA (eosinophilic granulomatosis with polyangiitis, Churg-Strauss)	p-ANCA (positive in only ~30–40%)	MPO	Asthma + eosinophilia (>10%) + vasculitis

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The classic EGPA question: recurrent asthma, palpable purpura, 27% eosinophils — the most specific test is ANCA, not total IgE and not ANA. But a negative ANCA cannot exclude EGPA (positivity is only 30–40%); in that case, rely on the asthma history, eosinophilia, and tissue biopsy.

Treatment principle: for severe disease (organ-threatening — renal/cardiac/neurologic/pulmonary hemorrhage), remission induction uses high-dose corticosteroids + cyclophosphamide or rituximab; the maintenance phase uses azathioprine / rituximab / methotrexate. Non-severe EGPA can add mepolizumab (anti-IL-5) to control eosinophils and spare corticosteroids.

Giant Cell Arteritis (GCA): Time Is Vision

Back to the 76-year-old woman from the opening. GCA favors patients >50 years old (often >70) and is frequently associated with polymyalgia rheumatica (PMR). Clinically it has four hallmarks: new-onset temporal headache, scalp tenderness, jaw claudication, and vision loss (anterior ischemic optic neuropathy, AION); ESR is markedly elevated.

The newer drug tocilizumab (an IL-6 receptor antagonist) can serve as a steroid-sparing agent, reducing relapse and cumulative steroid dose — a recently and frequently tested update.

Two Easily Confused Conditions: IgG4-Related Disease (IgG4-RD) and Hereditary Angioedema (HAE)

Disease	Mechanism	Features and workup
IgG4-related disease (IgG4-RD)	Infiltration by IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis	Can involve the periorbital region (lacrimal gland/orbit), salivary glands, pancreas (autoimmune pancreatitis), retroperitoneum; often associated with an atopic constitution and eosinophilia; elevated serum IgG4
Hereditary angioedema (HAE)	C1 inhibitor (C1-INH) deficiency/dysfunction → bradykinin accumulates	Recurrent non-pruritic subcutaneous/mucosal edema, can cause laryngeal edema; persistently low C4 is the screening clue; total IgE has no diagnostic value (a trap); antihistamines/corticosteroids/epinephrine are ineffective — requires a C1-INH concentrate or a bradykinin/kallikrein inhibitor

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

A paired mnemonic: HAE is "bradykinin" edema — it doesn't itch, doesn't depend on IgE, and doesn't respond to antihistamines; check C4 and C1-INH. This is nothing like the histamine-driven, itchy edema of urticaria, from mechanism all the way to treatment, and mixing the two up is a frequent point-loser on the exam.

Finally, polyarteritis nodosa (PAN) must have one frequently tested trap called out explicitly: PAN is a medium-vessel disease, often associated with HBV, spares the lung, ANCA is usually negative, and angiography shows beaded microaneurysms; its renal lesion is renovascular disease of the renal artery branches (infarction, microaneurysms, renovascular hypertension), and it typically does not cause glomerulonephritis — glomerulonephritis is a hallmark reserved for AAV (GPA/MPA). Mistaking PAN for an ANCA-associated vasculitis is a high-frequency wrong answer.

⭐ Board-exam essentials

Vasculitis and Related Diseases

Skeleton: large (GCA, Takayasu) / medium (PAN, Kawasaki) / small (ANCA-associated vs. immune complex).
c-ANCA(PR3) → GPA (upper airway + lung + kidney + granulomas); p-ANCA(MPO) → MPA, EGPA; for EGPA, a negative ANCA cannot exclude it (positivity 30–40%).
AAV is autoimmune, not autoinflammatory; mechanism = ANCA → neutrophil activation → NETs → small-vessel necrosis.
GCA: >50 years old, temporal pain, jaw claudication, high ESR; high-dose corticosteroids first, biopsy second; tocilizumab (IL-6) is a steroid-sparing agent.
Non-severe EGPA can add mepolizumab (anti-IL-5); induction for severe AAV = corticosteroids + cyclophosphamide or rituximab.
IgG4-RD: lacrimal gland/orbit, pancreas, salivary glands; elevated serum IgG4; storiform fibrosis.
HAE: C1-INH deficiency → bradykinin accumulates; low C4, total IgE useless; antihistamines / corticosteroids / epinephrine are ineffective.
PAN: medium vessel, associated with HBV, spares the lung, ANCA-negative, beaded aneurysms; typically does not cause glomerulonephritis (vs. AAV).
Traps: waiting for biopsy before treating GCA; checking total IgE for EGPA; treating HAE with antihistamines; classifying PAN as ANCA-associated.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・血管口徑的分類學Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

A referral letter to the clinic describes a seventy-six-year-old woman with new-onset temporal headache, jaw pain that stops her chewing halfway through, ESR spiking to ninety-five, and a left eye that hasn't been seeing too well lately; the resident is about to schedule a temporal artery biopsy, but the attending simply writes immediate high-dose corticosteroids and adds that the biopsy can wait. Vasculitis is a disease in which the immune system attacks the vessel wall, and the exam's skeleton is very simple: first sort by vessel caliber into large, medium, and small, then use ANCA subtype to pin down the small-vessel vasculitides. The large vessels are represented by giant cell arteritis and Takayasu arteritis — giant cell arteritis is the story of an elderly patient, the temporal artery, and vision, while Takayasu arteritis is the story of a young Asian woman with absent pulses. The medium vessels are represented by polyarteritis nodosa and Kawasaki disease — polyarteritis nodosa is often associated with hepatitis B, spares the lung, and shows beaded microaneurysms on angiography, while Kawasaki disease causes coronary artery aneurysms in children. The small vessels split into two camps: the ANCA-associated group of granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, and the immune-complex-driven group of IgA vasculitis and cryoglobulinemic vasculitis, the latter often associated with hepatitis C.

First sort by vessel caliber into large, medium, and small, then use ANCA subtype to pin down the small vessels — and the skeleton stands on its own.

The five-step mechanism of ANCA-associated vasculitis runs as follows: first, autoantibodies form against the neutrophil cytoplasmic enzymes PR3 or MPO; infection or environmental stimuli make neutrophils express these antigens on their surface; the moment ANCA binds, the neutrophils become hyperactivated, degranulate, and release NETs, attacking the small-vessel endothelium, and finally producing necrotizing vasculitis and necrotizing glomerulonephritis. It is therefore autoimmune, a different group from the autoinflammatory diseases of innate immune or inflammasome dysregulation, such as familial Mediterranean fever; the exam loves labeling granulomatosis with polyangiitis as autoinflammatory as a decoy, and remembering that it is autoimmune keeps you from being fooled. The three small-vessel vasculitides are split apart by whether the antigen is PR3 or MPO and whether the ANCA is c or p. Granulomatosis with polyangiitis, formerly called Wegener's, has the highest c-ANCA positivity rate with PR3 as its target; its clinical iron triad is upper-airway involvement such as sinusitis and saddle nose, lower-airway pulmonary nodules and cavities, and renal necrotizing glomerulonephritis, with granulomas seen on histology. Microscopic polyangiitis is p-ANCA with MPO as its target, likewise a pulmonary-renal syndrome but without granulomas and without upper-airway destruction. Eosinophilic granulomatosis with polyangiitis, or Churg-Strauss, is p-ANCA with MPO as its target, but ANCA positivity is only about thirty to forty percent, and its clinical iron triad is asthma, eosinophilia above ten percent, and vasculitis. The classic question gives recurrent asthma, palpable purpura, and twenty-seven percent eosinophils; the most specific test is ANCA, not total IgE and not ANA — but remember one trap: because positivity is only thirty to forty percent, a negative ANCA cannot exclude this disease, and diagnosis then still rests on the asthma history, eosinophilia, and a tissue biopsy showing necrotizing vasculitis with eosinophilic infiltration. As a treatment principle, severe disease with organ threat — kidney, heart, nerve, or pulmonary hemorrhage — has its remission induced with high-dose corticosteroids plus cyclophosphamide or rituximab, with azathioprine, rituximab, or methotrexate for maintenance; non-severe eosinophilic granulomatosis can add mepolizumab, an anti-IL-5 agent, to control eosinophils and spare corticosteroids.

First sort by vessel caliber into large, medium, and small, then use ANCA subtype to pin down the small vessels — and the skeleton stands on its own.

Giant cell arteritis is the representative large-vessel disease, favoring patients over fifty and often over seventy, frequently associated with polymyalgia rheumatica. Its four clinical hallmarks are new-onset temporal headache, scalp tenderness, jaw claudication, and vision loss, namely anterior ischemic optic neuropathy, with markedly elevated ESR. The iron rule of management is to give high-dose corticosteroids immediately on high suspicion, without waiting for the biopsy result; the logic behind this sequence is that once the optic nerve becomes necrotic from ischemia the damage is irreversible, and waiting a day or two for the biopsy could leave the patient blind, while the biopsy still retains diagnostic value for several days after corticosteroids are started, because the granulomatous changes in the vessel wall do not disappear right away — so the eye is saved first and the diagnosis sought second, rather than confirming first and treating second. The newer drug tocilizumab is an IL-6 receptor antagonist that can serve as a steroid-sparing agent, reducing relapse and cumulative steroid dose, a recently and frequently tested update. Two easily confused miscellaneous conditions deserve attention: IgG4-related disease involves infiltration by IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis, and can involve the periorbital region such as the lacrimal gland and orbit, the salivary glands, the pancreas causing autoimmune pancreatitis, and the retroperitoneum, often associated with an atopic constitution, eosinophilia, and elevated serum IgG4. Hereditary angioedema arises from C1 inhibitor deficiency or dysfunction, leading to bradykinin accumulation, recurrent non-pruritic subcutaneous and mucosal edema, and potential laryngeal edema; the screening clue is a persistently low C4, and total IgE having no diagnostic value is a trap — antihistamines, corticosteroids, and epinephrine are all ineffective, requiring a C1 inhibitor concentrate or a bradykinin or kallikrein inhibitor instead. The contrast worth writing in red is that hereditary angioedema is bradykinin edema — it doesn't itch, doesn't depend on IgE, and doesn't respond to antihistamines; check C4 and C1 inhibitor — utterly unlike the histamine-driven, itchy edema of urticaria, from mechanism all the way to treatment.

First sort by vessel caliber into large, medium, and small, then use ANCA subtype to pin down the small vessels — and the skeleton stands on its own.

Finally, polyarteritis nodosa deserves one frequently tested trap called out explicitly: it is a medium-vessel disease, often associated with hepatitis B, spares the lung, ANCA is usually negative, and angiography shows beaded microaneurysms; its renal lesion is renovascular disease of the renal artery branches, such as infarction, microaneurysms, and renovascular hypertension, and it typically does not cause glomerulonephritis — glomerulonephritis is a hallmark reserved for GPA and MPA among the ANCA-associated vasculitides, and mistaking polyarteritis nodosa for an ANCA-associated vasculitis is a high-frequency wrong answer. This whole chapter is really just one causal chain unfolding across different calibers and different antigens: the immune system manufactures a mistaken antibody, or a group of wrongly activated cells, that goes to war against the vessel wall, and the clinical picture then follows from the caliber and location of the vessel under attack. From the temporal artery to the sinuses, from the lung to the kidney, from skin purpura to laryngeal edema, every clinical clue traces back to some segment of vessel — hold the caliber-and-ANCA axis firmly in mind, and the questions sweep past with ease.

6. Civil War of the Synovium: Rheumatoid Arthritis (RA)

The Pathological Reasoning Chain: Autoimmunity Gnaws Outward from the Synovium into Bone

Clinical Presentation and Differentiation

Feature	Rheumatoid arthritis (RA)	Osteoarthritis (OA)
Nature	Autoimmune inflammation	Non-inflammatory, degenerative
Favored joints	MCP, PIP, wrist; symmetric polyarticular	DIP (Heberden's), PIP (Bouchard's), weight-bearing large joints
DIP involvement	Usually spares the DIP; DIP involvement should suggest concurrent OA	Common at the DIP
Morning stiffness	>1 hour, improves with activity	<30 minutes, worsens with activity
Inflammatory markers	ESR/CRP elevated	Usually normal
Imaging	Uniform joint-space narrowing, marginal erosion, osteopenia	Asymmetric space narrowing, osteophytes, subchondral sclerosis and cysts

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Serologically, sensitive must be distinguished from specific: RF is sensitive but not specific (Sjögren's and HCV can also be positive); anti-CCP is the most specific antibody, and it also predicts erosion and prognosis. The strongest genetic association is HLA-DR4 (the shared epitope) — RA's signature gene, not to be confused with AS's B27 or psoriasis's Cw6.

In its course, RA is predominantly symmetric and polyarticular, but can begin as a single joint early on — a frequently tested reversal trap; do not rigidly exclude a monoarticular onset.

Extra-Articular Manifestations: Most Common vs. Most Specific

Remember the extra-articular manifestations along two axes — frequency and specificity. The most common is osteoporosis (driven by inflammatory cytokines plus corticosteroids plus reduced activity), the invisible killer underlying RA as a whole (this is the exam key; many textbooks instead name rheumatoid nodules as the most common). The most specific are the rheumatoid nodule (extensor surfaces, associated with high-titer RF) and Felty syndrome (the three-piece set of RA + splenomegaly + neutropenia — forgetting the low blood count costs you points).

Pulmonary manifestations include interstitial lung disease (ILD) and pleural effusion; the pleural effusion has a signature feature — an extremely low glucose. Ocular involvement is secondary Sjögren's, with dryness plus scleritis. Caplan syndrome is RA plus pneumoconiosis (silicosis/coal-worker's) → multiple pulmonary nodules. The cardiovascular system, meanwhile, undergoes accelerated atherosclerosis driven by chronic inflammation — cardiovascular disease is RA's leading cause of death, not joint destruction itself.

Finally, there is one high-frequency safety point: C1–C2 atlantoaxial subluxation — RA's chronic inflammation destroys the C1–C2 ligaments, loosening this vertebral segment relative to the odontoid process. If the neck is hyperextended during intubation, it can compress the spinal cord or medulla with catastrophic results. So RA patients must have their cervical spine assessed before intubation for general anesthesia — a rule that anesthesiology and rheumatology both agree on, and it is tested without fail every time.

The Treatment Ladder: MTX Is the Cornerstone, and Pregnancy Calls for Switching Sides

The iron rule of treatment is early and aggressive (treat-to-target), aiming for remission or low disease activity — delaying treatment is the same as letting the pannus gnaw away at bone unchecked.

Stage	Drug	Key point
Symptom bridging	NSAID / short-course low-dose corticosteroid	Does not alter disease course; must not be used alone long-term
First-line DMARD (cornerstone)	methotrexate (MTX)	Co-administered with folate to reduce side effects; contraindicated in pregnancy (teratogenic)
MTX failure	Biologics: anti-TNF, an IL-6 inhibitor (tocilizumab), abatacept, rituximab; or a JAK inhibitor	Tocilizumab is used after an inadequate response to MTX

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Medication in pregnancy is a high-frequency exam topic — cut it cleanly along "teratogenic vs. safe":

Relatively safe throughout pregnancy	Contraindicated in pregnancy (teratogenic/adverse)
Hydroxychloroquine (HCQ), sulfasalazine (with folate supplementation), low-dose corticosteroids, certolizumab if needed	Methotrexate, leflunomide (requires cholestyramine washout), cyclophosphamide, mycophenolate

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

For an RA patient planning pregnancy, remember one sentence: stop MTX and leflunomide, switch to HCQ and sulfasalazine. Leflunomide still needs a cholestyramine washout to be cleared out completely.

⭐ Board-exam essentials

Rheumatoid Arthritis (RA)

Mechanism = autoimmunity → pannus gnaws bone from the inside out; five steps = HLA-DR4 + environment → citrullination + anti-CCP/RF → synovial infiltration → pannus releases MMP/RANKL/TNF-α/IL-6 → marginal bone erosion.
MCP / PIP / wrist, symmetric, morning stiffness >1 hour; usually spares the DIP (DIP involvement suggests concurrent OA); can begin as a single joint early on.
anti-CCP is the most specific (predicts prognosis/erosion); RF is sensitive but not specific; gene = HLA-DR4 (shared epitope).
Extra-articular: osteoporosis is most common; rheumatoid nodules and Felty syndrome (RA + splenomegaly + neutropenia) are most specific; pleural effusion has extremely low glucose; Caplan = RA + pneumoconiosis; leading cause of death = cardiovascular disease.
C1–C2 atlantoaxial subluxation: the cervical spine must be assessed before intubation for general anesthesia.
Treatment: MTX is the cornerstone; on failure, use anti-TNF / IL-6 (tocilizumab) / abatacept / rituximab / a JAK inhibitor.
Pregnancy: safe = HCQ, sulfasalazine (with folate), low-dose corticosteroids, certolizumab; contraindicated = MTX, leflunomide (requires cholestyramine washout), cyclophosphamide, mycophenolate.
Traps: keeping MTX during pregnancy; assuming RA always involves the DIP; forgetting the neutropenia in Felty syndrome; forgetting to assess the cervical spine before intubation; treating RF as the most specific antibody.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・滑膜的內戰Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

A forty-eight-year-old woman has symmetric swelling of the metacarpophalangeal joints of both index and middle fingers, morning stiffness lasting more than two hours, both ESR and C-reactive protein elevated, and a strongly positive anti-cyclic citrullinated peptide antibody; she says she is too tired even to carry her dinner plate, and lately she has also been short of breath, with the chest film showing a small pleural effusion. The core causal chain of rheumatoid arthritis strings together in five steps: first the genetic HLA-DR4 shared epitope plus environmental factors such as smoking or periodontal bacteria, then proteins are citrullinated, producing the anti-cyclic citrullinated peptide antibody and rheumatoid factor, the synovium is activated and infiltrated by CD4 T cells and B cells, synovial proliferation forms pannus that releases matrix metalloproteinases, RANKL, TNF, and IL-6, and finally bone erosion is gnawed out from the inside, starting at the joint margin. The key imaging finding is therefore marginal bone erosion rather than bone spurs; long-standing disease deforms into ulnar deviation, swan-neck deformity, and boutonnière deformity.

Rheumatoid arthritis is pannus gnawing marginal erosion from the inside out — so anti-CCP is the most specific, and cardiovascular disease is the true leading cause of death.

Serologically, rheumatoid arthritis requires distinguishing sensitive from specific: rheumatoid factor is sensitive but not specific, since Sjögren's and hepatitis C can also be positive, while the anti-cyclic citrullinated peptide antibody is the most specific antibody and can also predict erosion and prognosis; the strongest genetic association is the HLA-DR4 shared epitope, the signature gene of rheumatoid arthritis, not to be confused with ankylosing spondylitis's B27 or psoriasis's Cw6. In its course, rheumatoid arthritis is predominantly symmetric and polyarticular but can begin as a single joint early on, a frequently tested reversal trap — do not rigidly exclude a monoarticular onset. In terms of joint distribution, rheumatoid arthritis involves the metacarpophalangeal joints, proximal interphalangeal joints, and wrist in a symmetric polyarticular pattern, usually sparing the distal interphalangeal joints; involvement there should suggest concurrent degenerative disease. Extra-articular manifestations fall along two axes of frequency and specificity: the most common is osteoporosis, produced by the triple blow of inflammatory cytokines, corticosteroids, and reduced activity, the invisible killer underlying rheumatoid arthritis as a whole; the most specific are the rheumatoid nodule, found on extensor surfaces and associated with high-titer rheumatoid factor, and Felty syndrome, the three-piece set of rheumatoid arthritis plus splenomegaly plus neutropenia — forgetting the low blood count costs you points.

Rheumatoid arthritis is pannus gnawing marginal erosion from the inside out — so anti-CCP is the most specific, and cardiovascular disease is the true leading cause of death.

Pulmonary manifestations include interstitial lung disease and pleural effusion, with the pleural effusion carrying a signature feature of extremely low glucose; ocular involvement is secondary Sjögren's plus scleritis; Caplan syndrome is rheumatoid arthritis plus pneumoconiosis such as silicosis or coal-worker's disease, producing multiple pulmonary nodules; cardiovascular disease represents accelerated atherosclerosis driven by chronic inflammation and is rheumatoid arthritis's leading cause of death, not joint destruction itself. One high-frequency safety point is C1–C2 atlantoaxial subluxation: rheumatoid arthritis's chronic inflammation destroys the ligaments between C1 and C2, loosening this vertebral segment relative to the odontoid process, and if the neck is hyperextended during intubation it can compress the spinal cord or medulla with catastrophic results — so rheumatoid arthritis patients must have their cervical spine assessed before intubation for general anesthesia, a consensus shared by anesthesiology and rheumatology that is tested without fail every time.

Rheumatoid arthritis is pannus gnawing marginal erosion from the inside out — so anti-CCP is the most specific, and cardiovascular disease is the true leading cause of death.

The iron rule of treatment is early and aggressive management aiming for remission or low disease activity, since delaying treatment is the same as letting the pannus gnaw away at bone unchecked. Symptom bridging uses anti-inflammatory analgesics or a short course of low-dose corticosteroids, but this does not alter the disease course and must not be used alone long-term; the cornerstone first-line disease-modifying antirheumatic drug is methotrexate, co-administered with folate to reduce side effects, and contraindicated in pregnancy because it is teratogenic; when methotrexate fails, biologics such as an anti-TNF agent, an IL-6 inhibitor such as tocilizumab, abatacept, or rituximab are used, or else a JAK inhibitor. Medication in pregnancy calls for switching sides rather than stopping treatment altogether, since stopping everything would let the disease flare massively and harm the fetus and mother instead; the teratogenic drugs that must be stopped are methotrexate and leflunomide, with leflunomide additionally requiring a cholestyramine washout to be cleared out completely, switching instead to the pregnancy-safe quinine-class hydroxychloroquine and sulfasalazine with folate supplementation, adding the Fc-fragment-truncated certolizumab if needed, with low-dose corticosteroids also considered safe. Hold onto the main line of the synovium gnawing bone throughout this chapter, and everything from imaging, blood work, and extra-articular disease to medication in pregnancy follows naturally from it.

7. Wear and Failed Repair: Osteoarthritis (OA)

Pathological Mechanism: Wear Plus Failed Repair, Not Immune Attack

OA's clinical features and risk factors tell the classic story of "mechanical pain plus reparative bone overgrowth": pain with activity, relief with rest, morning stiffness <30 minutes; it favors the hand's DIP (Heberden's), PIP (Bouchard's), first carpometacarpal joint, knee, hip, and spine; it typically spares the MCP and wrist joints — involvement of the MCP should raise suspicion of another disease (hemochromatosis, CPPD). Risk factors are advanced age, female sex, obesity (especially for the knee), joint trauma/overuse, genetic susceptibility, and poor mechanical alignment.

Joint Fluid Analysis: The Main Axis for Sorting Inflammatory from Non-Inflammatory

Type	Appearance/viscosity	WBC (/μL)	Predominant cells	Representative
Normal	Clear, viscous	<200	Mononuclear cells	—
Non-inflammatory (OA)	Clear, viscous	200–2000 (often <2000)	Predominantly mononuclear	Osteoarthritis
Inflammatory	Cloudy, viscosity↓	2000–50,000	Neutrophils	RA, gout, CPPD
Infectious (septic)	Purulent	>50,000 (often >100,000)	Neutrophils	Septic arthritis

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Remember two frequently tested clinical vignettes: first, an 80-year-old with knee pain and joint fluid that is viscous, WBC about 100, predominantly mononuclear — the answer is osteoarthritis. Second, a well-controlled RA patient develops a single joint effusion with a WBC of only about 800 (within the low-grade inflammatory range) — this is most likely concurrent OA, not RA worsening or infection.

The Treatment Ladder and One Differential Not to Get Wrong

OA's stepped treatment has two points that keep getting revised — use the current ACR/OARSI version:

Stage	Management	Key point
Foundation (first-line non-pharmacologic)	Weight loss, exercise/strength training, patient education, assistive devices	The long-term intervention with the strongest evidence for knee/hip OA
Pharmacologic	(Knee) topical NSAID preferred → oral NSAID (weigh GI/renal/cardiac risk)	An oral NSAID is not the automatic first choice >90% of the time; high-risk patients get topical treatment first. Acetaminophen has limited efficacy and is no longer a mainstay, reserved only as a fallback when NSAIDs are contraindicated
Local	Intra-articular corticosteroid (short-term relief)	Evidence for intra-articular hyaluronic acid is weak; ACR 2019 issues a conditional "against" recommendation for knee/hip OA — do not treat it as routine
End stage	Joint replacement	When disease is severe and conservative measures fail

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

One final differential trap: an imaging abnormality confined to a single wrist bone is not OA.

Clue	Think of
Lunate abnormality/collapse on X-ray	Avascular necrosis = Kienböck disease
Non-union after a scaphoid fracture	Avascular necrosis of the scaphoid
Hand MCP involvement + chondrocalcinosis + iron overload	Arthropathy associated with hemochromatosis

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

⭐ Board-exam essentials

Osteoarthritis (OA)

Mechanism = MMPs degrade cartilage + failed repair (not pure physical abrasion); CRP/ESR normal.
Five steps = mechanical loading + aging → MMP/ADAMTS degradation → cartilage thinning and fissuring → subchondral sclerosis + osteophytes → mechanical pain.
Favored sites = DIP / PIP / first carpometacarpal / knee / hip / spine; spares the MCP / wrist (involvement there suggests hemochromatosis, CPPD).
Imaging: asymmetric joint-space narrowing, osteophytes, subchondral sclerosis and cysts (vs. RA's symmetric narrowing + marginal erosion + osteopenia).
Joint fluid: clear and viscous, WBC <2000, predominantly mononuclear; a low-grade single-joint effusion in an RA patient most likely means concurrent OA.
Treatment: non-pharmacologic (weight loss, exercise) as first line; knee gets topical NSAID preferred; ACR 2019 conditionally recommends against hyaluronic acid; acetaminophen has limited efficacy.
Differential: lunate collapse = Kienböck disease; MCP involvement + iron overload should suggest hemochromatosis.
Traps: assuming OA raises CRP; answering the mechanism as pure physical abrasion; using hyaluronic acid as routine therapy; misreading lunate collapse as OA.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　風濕免疫・磨損與失敗的修復Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・風濕免疫》 · the text below is an English rendering of the lyrics

Next into the clinic comes a seventy-year-old woman with hard Heberden's nodes at her distal interphalangeal joints, knee pain when climbing stairs that worsens the longer she is active, and a C-reactive protein that comes back completely normal; she says she played volleyball for twenty years when she was young. The core sentence for osteoarthritis is that it is mechanical wear of cartilage plus failed repair, not an immune attack. The five-step mechanism strings together like this: mechanical loading and aging come first, chondrocytes release matrix metalloproteinases and ADAMTS to degrade collagen and proteoglycans, cartilage thins and fissures, the subchondral bone is forced to sclerose and grows osteophytes and cysts at its margins, and finally the disease presents as mechanical pain and joint deformity. Systemic inflammatory markers are therefore usually normal, which is exactly the root reason the two diseases sit at opposite poles on both imaging and blood work; trap questions often describe the mechanism as cartilage simply being worn away, but the correct answer is to remember that matrix metalloproteinases enzymatically degrade the cartilage, not pure physical abrasion.

Osteoarthritis is MMPs enzymatically degrading cartilage and growing reparative bone spurs — so the markers stay normal, and it is spurs, not erosion.

Osteoarthritis's clinical features and risk factors tell the classic story of mechanical pain plus reparative bone overgrowth: pain with activity, relief with rest, morning stiffness under thirty minutes, favoring Heberden's nodes at the hand's distal interphalangeal joints, Bouchard's nodes at the proximal interphalangeal joints, the first carpometacarpal joint, the knee, the hip, and the spine, typically sparing the metacarpophalangeal and wrist joints; involvement of the metacarpophalangeal joints should suggest hemochromatosis or calcium pyrophosphate deposition arthropathy. Risk factors are advanced age, female sex, obesity especially of the knee, joint trauma or overuse, genetic susceptibility, and poor mechanical alignment.

Osteoarthritis is MMPs enzymatically degrading cartilage and growing reparative bone spurs — so the markers stay normal, and it is spurs, not erosion.

The logic for reading joint fluid analysis fits in one sentence: look at clarity, viscosity, white cell count, and cell type, with the white cell count as the main axis for sorting inflammatory from non-inflammatory — the higher the white cell count and the more neutrophils present, the closer you are to the infection end of the spectrum. Osteoarthritic joint fluid, having no inflammation, retains the viscosity of its high hyaluronic acid content, with a white cell count usually under two thousand and monocytes predominating, so an eighty-year-old with knee pain whose joint fluid is viscous, with a white cell count of about a hundred and predominantly mononuclear, points to osteoarthritis. One frequently tested extension is a well-controlled rheumatoid arthritis patient who develops a single joint effusion with a white cell count of only about eight hundred, within the low-grade inflammatory range — this is most likely concurrent osteoarthritis, not rheumatoid arthritis worsening or infection.

Osteoarthritis is MMPs enzymatically degrading cartilage and growing reparative bone spurs — so the markers stay normal, and it is spurs, not erosion.

The treatment ladder has two points that keep getting revised, so use the current version: first line is non-pharmacologic — weight loss, exercise, strength training, patient education, assistive devices — the intervention with the strongest evidence for long-term management of knee and hip osteoarthritis; for medication, the knee gets topical anti-inflammatory analgesics preferred, because elderly patients carry high GI/renal/cardiac risk, and an oral anti-inflammatory analgesic is not automatically the first choice over ninety percent of the time — risk must be assessed; acetaminophen has limited efficacy and is no longer a mainstay, reserved only as a fallback when contraindicated. Locally, intra-articular corticosteroids give short-term relief; evidence for intra-articular hyaluronic acid is weak, and the 2019 guideline conditionally recommends against it for the knee and hip — do not treat it as routine; joint replacement comes only at the end stage. One final differential trap deserves emphasis: an imaging abnormality confined to a single wrist bone is not osteoarthritis — lunate abnormality or collapse on X-ray is avascular necrosis, namely Kienböck disease; non-union after a scaphoid fracture is avascular necrosis of the scaphoid; and hand metacarpophalangeal involvement plus chondrocalcinosis plus iron overload should suggest hemochromatosis-associated arthropathy. Hold onto the main line of cartilage being enzymatically degraded by matrix metalloproteinases throughout this chapter, and everything from imaging, blood work, and joint fluid to the treatment ladder follows naturally from it, with the pairings growing on their own once you understand it.